Core Viewpoint - IMCD N.V. has announced the acquisition of 100% of the shares in Trichem Healthcare Private Limited, Trichem Lifesciences Limited, and Chemistry & Health FZ LLC, enhancing its portfolio in the life-sciences industry, particularly in active pharmaceutical ingredients [1][4]. Company Overview - IMCD is a global leader in the distribution and formulation of specialty chemicals and ingredients, headquartered in Rotterdam, The Netherlands [5]. - In 2024, IMCD reported revenues of EUR 4,728 million and employed over 5,100 staff [6]. Trichem Overview - Trichem, founded in 1998 and based in Mumbai, India, specializes in supplying high-quality active pharmaceutical ingredients and pharmaceutical intermediates, along with regulatory assistance for the pharmaceutical markets in India [2]. - The company operates with 36 employees and generated annual revenue of approximately INR 1.7 billion (around EUR 18 million) for the financial year ending 31 March 2025, with 33% of this revenue derived from commission income [3]. Strategic Importance - The acquisition is positioned to strengthen IMCD's presence in the Indian market, which is a major supplier of generic drugs globally, and to leverage Trichem's market expertise and industry relationships [4].